TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
KROS

Keros Therapeutics Inc

Healthcare · Biotechnology

11.60$ +0.6% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow KROS
Line item 2018 2019 2020 2021 2022 2023 2024 2025
70.4% -160.0% -1,475.8% -309.2% -350.3% -82,455.6% -4,531.5% 44.0%
1.5% 4.4% 11.1% 1.9% 3.4% 539.7% 34.6% 0.6%
0.8% 0.6% 163.9% 58.3% 93.4% 19,048.3% 982.3% 11.8%
2.8% 28.5% 236.6% 58.5% 93.5% – – –
79.5% -67.2% 91.0% -80.0% 71.5% -1,755.0% -322.2% -5.0%
2.2% 2.7% 11.8% 5.1% 6.2% 1,631.8% 54.4% 0.6%
-2.2% -2.7% -11.8% -5.1% -6.2% -1,631.8% -54.4% -0.6%
115.1% 0.1% 11,960.5% 142.0% 601.5% – 0.0% -153.7%
– – -16.8% – – – – –
114.6% 0.1% 11,841.8% 142.0% 601.5% 118,513.9% 11,037.2% -155.1%
182.9% -162.4% 10,354.2% -172.2% 245.0% 34,426.5% 6,451.3% -111.7%
68.3% -162.7% -1,487.5% -314.3% -356.5% -84,087.4% -4,585.9% 43.4%

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?